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RNA transcripts have emerged as key regulators of diverse biological phenomena. Classically RNA was viewed as a carrier of genetic information that exists solely to transmit a message for protein coding and guide the process of protein biosynthesis. Modern views encompass an expanded role for RNA, with a diverse range of RNA molecules now understood to have broad and far-reaching roles in modulating gene expression and other biological processes by various mechanisms ([@bib14]). One recent report estimated that while ∼85% of the human genome is transcribed into RNA, only ∼3% of those transcripts code for protein, indicating that vast majority of RNAs are noncoding ([@bib45]). Furthermore, a large number of newly discovered noncoding RNAs are disease associated, both in cancer and nontumorigenic diseases ([@bib17], [@bib33]). Thus, the realization that RNAs contribute to disease states apart from coding for pathogenic proteins is likely to provide a wealth of previously unrecognized therapeutic targets ([@bib22]). Given that many of these RNAs adopt discrete secondary and tertiary structures and have pivotal roles in biology, they are attractive targets for small molecules.

In mammals, the biological functions of RNAs are highly diverse and act at many levels of regulation. RNAs vary greatly in sequence length, ranging from small hairpins consisting of a few nucleotides to long noncoding RNAs (lncRNAs) consisting of several thousand nucleotides. One example of small RNA molecules is microRNAs (miRNAs), which are approximately 22 nucleotide sequences produced by DICER processing of RNA hairpins, and function to suppress gene expression by inhibiting or degrading mRNAs. Another example of a noncoding RNA is telomeric repeat RNA (TERRA), which consists of oligomeric sequences of polymorphic RNA G-quadruplexes and is believed to be required for proper telomere function ([@bib80]). Oligonucleotide repeat expansion diseases are a series of pathologies that occur when oligomeric expansions of RNA result in a disease state, such as (CAG)~n~ in Huntington\'s disease ([@bib37]) or (GGGCCC)~n~ in amyotrophic lateral sclerosis (ALS) ([@bib26]). Larger lncRNAs such as HOTAIR, and many others, contribute to oncogenesis through direct binding and sequestration of various tumor suppressors and other proteins, although this mechanism is not always clear ([@bib17]). New families of functional, noncoding RNAs continue to be discovered, including PIWI-interacting RNAs, small nuclear RNAs, small nucleolar RNAs, and others ([@bib33]). In addition to canonical, noncoding RNA sequences, alternative splicing of an mRNA can provide multiple gene products from the same transcribed RNA sequence; the misregulation of this process is often disease associated ([@bib85]). Posttranscriptional modifications such as methylation have also been discovered to modulate RNA structure and function ([@bib19], [@bib46], [@bib59]).

Apart from mammalian systems, RNA plays a pivotal role in both viruses and bacteria. The orthogonality of homologous functional elements between viral or bacterial transcriptomes/genomes and mammalian transcriptomes makes these RNA structures excellent targets for anti-infective drugs, a concept that has gained significant attention. Historically, genomes of retroviruses such as HIV have been shown to contain noncoding, *cis*-acting functional elements such as the transactivation response (TAR) hairpin, the frameshift signal (FSS), or the Rev responsive element (RRE) ([@bib56]). These RNAs have multifunctional roles that regulate polymerase activity, viral infectivity, and progression at multiple levels and have been studied as drug targets. Similarly, viral RNAs such as the internal ribosomal entry site (IRES) enable cap-independent translation and have been studied as therapeutically relevant targets in both poliovirus and hepatitis C virus (HCV) ([@bib25]). Bacteria also contain naturally occurring RNA aptamers called riboswitches that bind to secondary metabolites and regulate gene expression in bacteria. More recent work demonstrated that riboswitches are not unique to bacteria, and these RNAs have emerged as a major area of study in RNA biology, ranging from serving as model systems to study RNA structure to potential drug targets ([@bib14]).

In addition to new functions, the development of modern analytical techniques has ushered in an explosion in our knowledge of RNA structure. Early views tended to consider RNAs as highly flexible molecules largely devoid of discrete structure. However, current views consider RNA to exist as a dynamic ensemble of structural conformations, including well-defined secondary and tertiary folds ([@bib84]). Traditionally, X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy have been the two techniques used to characterize atomic-resolution RNA structures. Although not without technical challenges, both of these methods yielded profound insights and high-resolution structures of RNA molecules with a range of sizes and structural features. Cryoelectron microscopy (cryo-EM) has recently undergone a revolution in the resolution it can achieve and now competes with X-ray crystallography in terms of the structural analysis of increasingly large RNA structures ([@bib40]). On the other hand, advances in NMR spectroscopy and computational modeling have been critical in developing the view of RNAs as dynamic systems ([@bib90]). Another complementary biophysical technique, small-angle X-ray scattering (SAXS), is also emerging as a powerful way to analyze the fold adopted by a particular RNA in solution, as it offers a view of a global shape ([@bib34]). Chemical probing techniques such as selective 2′-hydroxyl acylation analyzed by primer extension (SHAPE) have further proved highly useful in evaluating RNA structure at single-nucleotide resolution, and an entire viral genome may now be structurally analyzed in a single experiment ([@bib97]). A frontier in this area is the application of such probing techniques to RNA structures in vivo, with a goal of confirming the biologically relevant conformations of RNA ([@bib89]).

Despite the development of such powerful techniques for the analysis of RNA structure and discovery of new function, our ability to identify or design inhibitors that bind to and perturb the function of RNA lags far behind. To date, the most commonly employed method to target disease-associated RNAs is based on the use of antisense technologies such as small interfering RNAs. Antisense technology is highly effective, and a small number of drugs using this approach have been approved ([@bib64]). However, this approach primarily relies on derivatized oligonucleotide structures, which suffer from poor cell permeability and distribution due to their requisite anionic character, limiting their application as therapeutics. Small molecules, however, often offer the advantage of having desirable properties such as good absorption, distribution, and oral bioavailability. In addition, small molecules have the potential to recognize RNA by virtue of secondary or tertiary structure, as opposed to sequence. Thus, small molecules provide an orthogonal means to target different RNA structural elements such as bulges, loops, junctions, pseudoknots, or higher-order structure by virtue of recognizing and binding unique folds, rather than complementary sequence.

Early approaches to identify RNA-binding molecules led to the discovery of aminoglycosides, potent, clinically used molecules that bind to RNA through electrostatic interactions with, at best, modest selectivity and systemic toxicity. However, more recent approaches have favored the development of more drug-like RNA-binding compounds that display improved physiochemical properties and more well-defined patterns of selectivity. For the purposes of this review, we use the term "drug-like" to refer to compounds predicted or demonstrated to have good medicinal chemistry properties such as potency, solubility, selectivity, distribution, and in some rare cases oral bioavailability. These compounds tend to have molecular weight below ∼500, fewer than five hydrogen-bond donors/acceptors, low polar surface area, and no reactive/promiscuous scaffolds. A desirable feature of such compounds is that they interact with RNA not through intercalation, or sequence or electrostatic complementarity, but by means of specific molecular recognition events unique to the particular RNA target. New techniques are increasingly required to define the rules for identifying, designing, and studying RNA-binding small molecules, and advancing these molecules as biological probes and potential therapeutics. However, overcoming the challenges of the highly anionic nature of RNA, compounded by its flexible, dynamic structure, remains the main roadblock for the development of small-molecule inhibitors. Moreover, many putative small-molecule binding sites in RNA are much more polar and solvent exposed than binding sites on proteins, complicating ligand design efforts. Despite these challenges, there have been a number of promising results reported recently suggesting that the long sought-after goal of developing small-molecule drugs that target RNA may indeed be achievable. This review discusses recent developments in technologies and approaches used to identify such inhibitors. We focus mostly on advances reported since several other comprehensive reviews ([@bib32], [@bib42], [@bib56], [@bib93]) and exclude ribosome-binding molecules, as these have been well reviewed elsewhere ([@bib1], [@bib48], [@bib77]).

Design- and Structure-Based Approaches {#sec1.2}
--------------------------------------

The flexible and dynamic nature of RNA structures represents one of the challenges associated with targeting RNAs with small molecules. However, the ability to identify small molecules that bind to specific RNA targets through structure-based approaches that take dynamics into account provides a viable avenue to identify potent binders ([@bib87]). In a recent example, the Al-Hashimi laboratory has successfully used NMR residual dipolar coupling data to calculate a dynamic ensemble of the HIV-1 TAR element RNA, a prominent target for the inhibition of HIV replication ([@bib56]). The dynamic ensemble was then used as a starting point for a virtual screen to identify small molecules that target the entire structural landscape of TAR ([@bib90]). A 51,000-member small-molecule library was screened against 20 conformers of the TAR ensemble to identify six small molecules, including netilmicin (**1**) and 5-(N,N)-dimethylamiloride (**2**) ([Figure 1](#fig1){ref-type="fig"}A), which bind to TAR with high affinity (K~D~ = 55 nM to 122 μM) and inhibit its interaction with the Tat peptide in vitro with K~i~ values ranging from 710 nM to 169 μM. Several of the identified compounds showed significant deterioration in the binding affinities when measured in the presence of excess tRNA, indicating nonspecific tRNA binding; however, no change in the K~D~ values for **1** and **2** was observed. Furthermore, netilmicin was found to selectively bind TAR over other RNAs that resemble the TAR hairpin, including an HIV-2 TAR variant (negligible affinity), the prokaryotic ribosomal A-site hairpin (35-fold weaker affinity), and the HIV-1 RRE hairpin (86-fold weaker affinity). In addition, netilmicin bound to a TAR mutant with a deletion of a single cytosine bulge residue with 16-fold weaker affinity than wild-type TAR. Netilmicin also showed unique interactions involving the bulge, upper stem, and apical loop of TAR as determined by NMR chemical shift mapping experiments. In addition, netilmicin specifically inhibited Tat-mediated activation of the HIV-1 promoter by 81% in T cell lines and inhibited HIV-1 replication in an HIV-1 indicator cell line, TZM-bl, and the HIV-1 NL4-3 isolate, with an IC~50~ value of ∼23 μM. Taken together, the discovery of netilmicin as a potent binder of TAR demonstrates the ability to use NMR-informed computational dynamic ensembles as a suitable foundation for identifying RNA-targeting small molecules.Figure 1Structure- and Design-Based Approaches for Identifying RNA-Binding Molecules(A) Representative conformers of wild-type HIV-1 TAR RNA (left) used to identify TAR-binding small molecules (right) by virtual screening ([@bib90]).(B) Crystal structure of the HCV IRES subdomain IIa RNA in complex with the benzimidazole inhibitor **4** showing the small-molecule-induced change in the interhelical angle of the RNA (left), and structures of the identified HCV translation inhibitors that bind to subdomain IIa (right) ([@bib76]).(C) Structure of the r(CUG)~6~ duplex (left) used to rationally design a highly selective CUG binding ligand **5** based on the triaminotriazine scaffold (right) ([@bib68], [@bib99]). Structures of r(CUG)^exp^ binding compounds **6** and **7** identified by high-throughput screening efforts are also shown (right) ([@bib21], [@bib83]).(D) Representative structure of a three-way junction (left) for which RNA-binding triptycene-based scaffolds such as compound **8** (right) were developed ([@bib4]).(E) Structure of the SARS-CoV RNA pseudoknot involved in an essential −1 ribosomal frameshift (left) used in a virtual screen to identify a SARS-pseudoknot-binding ligand (right) ([@bib75]).

In another RNA virus, the IRES of HCV binds to the host cell\'s ribosomal 40S subunit, initiates viral translation in a cap-independent fashion, and adopts an ordered structure dominated by independently folded RNA domains ([@bib76]). The Hermann laboratory reported the three-dimensional structure of the IRES subdomain IIa determined by X-ray crystallography and showed that it adopts an overall bent architecture with an L-shaped conformation that is stabilized by three divalent metal ions ([@bib27]). Importantly, the determined L-shaped conformation is in agreement with previously reported NMR studies on the full domain II ([@bib60]) and cryo-EM investigations of IRES-40S complexes ([@bib10], [@bib88]). It is likely that maintaining the architecture of subdomain IIa is critical for correct binding of the viral mRNA at the ribosome. A high-throughput screen of a 180,000-member library against a 29-mer oligonucleotide representing the IRES subdomain IIa using a mass spectrometry-based screening method identified a benzimidazole-containing compound with a K~D~ of ∼100 μM to the IRES IIa model ([@bib86]). Subsequently, a new class of benzimidazole-containing compounds was developed after extensive structure-activity relationship studies, and several analogs were identified with submicromolar affinity ([Figure 1](#fig1){ref-type="fig"}B). Using information gathered from crystallography, Hermann and coworkers developed several fluorescence-based assays to assess the binding of the benzimidazole-based ligands to the RNA ([@bib76]). A fluorescence resonance energy transfer (FRET)-based assay monitoring the interhelical angle between the stems flanking the internal loop in IIa via a measurement of the distance between the stem termini was developed and used to determine the ability of the benzimidazole (**3**) to bind to an oligonucleotide mimic of IRES IIa. Addition of the benzimidazole (**3**) resulted in a dose-dependent quenching of FRET with an EC~50~ value of 0.6 μM in 2 mM Mg^2+^ and was unchanged in the presence of excess competitor tRNA. These data suggest that the benzimidazole acts as an HCV translation inhibitor by inducing a conformational widening of the interhelical angle in the IRES subdomain IIa RNA. In addition, the impact of **3** on HCV translation was assessed in human cells expressing a reporter under control of the HCV IRES, and the compound successfully inhibited IRES-driven translation at low micromolar concentrations. X-ray crystallographic analysis of subdomain IIa in complex with a benzimidazole ligand (**4**, [Figure 1](#fig1){ref-type="fig"}B) verified the widening of the interhelical angle ([@bib28]). The initial benzimidazole ligands were further explored through subsequent rounds of synthesis of rationally designed ligands based on the cocrystal structure of the IIa RNA in complex with the ligand ([@bib29], [@bib82]). Recent cryo-EM studies indicate that domain IIa adopts a bent conformation in complex with the 80S- and 40S-ribosomal subunits ([@bib79], [@bib100]). Therefore, the more linear ligand-bound IIa domain structure identified by crystallography may prevent the conformation necessary for this interaction ([@bib100]). Additional screening of subdomain IIa RNA with modular ligands that contain the 3,5-diaminopiperidine heterocycle revealed *N*-amido substituted α-amino acid conjugates that bind subdomain IIa with micromolar affinities and arrest the RNA in a bent state with a 90° interhelical angle in solution ([@bib16]). Further adaptation of the previously mentioned structure-based FRET assay monitoring the interhelical angle of the IIa RNA to a high-throughput screening format has also led to the identification of additional IIa RNA-binding compounds ([@bib105]).

A rational design approach was similarly extended to the development of small molecules that bind to the r(CUG)^exp^ (expansion of r(CUG) repeats) RNA associated with myotonic dystrophy type 1 (DM1). DM1 is a multisystem disorder that affects skeletal and smooth muscle as well as the eye, heart, endocrine system, and CNS, causing symptoms including myotonia, wasting of the muscle, and cardiac defects. r(CUG)^exp^ is located in the 3′ UTR of the dystrophia myotonica protein kinase mRNA and causes disease through a gain-of-function mechanism, whereby the RNA binds to and sequesters proteins involved in RNA biogenesis, such as the MBNL (muscleblind-like) family of splicing regulators. Based in part on a previously developed ligand for the HIV-1 frameshift site RNA stem loop and on the X-ray crystal structure of r(CUG)~6~, the Zimmerman group designed an RNA-groove-binding inhibitor (**5**) for r(CUG)^exp^ comprising two triaminotriazine units connected by a bisamidinium linker ([Figure 1](#fig1){ref-type="fig"}C) ([@bib99]). The triaminotriazine units were selected for their propensity to form base triplets with U-U mismatches (and are known as Janus-wedge units), while the bisamidinium moiety was suggested as a groove-binding scaffold for CUG recognition. Compound **5** exhibited low micromolar affinity (K~D~ = 8 ± 2 μM) for r(CUG)~12~ by ITC, showed selective binding over other targets including tRNA, glutathione S-transferase-tagged MBNL1, HIV-1 frameshift site RNA, and r(CCUG)~8~, and was capable of disrupting the MBNL1-r(CUG)~12~ interaction in vitro with an apparent K~i~ of 8 ± 2 μM as determined by electrophoretic mobility shift assay. The compound showed good cell permeability in vitro, reduced MBNL1-r(CUG)^exp^ ribonuclear foci formation in a cell-culture model for DM1, and partially restored the misregulated splicing of two pre-mRNAs, cardiac troponin T (cTNT) and insulin receptor. In vivo, the compound suppressed the phenotype associated with r(CUG)^exp^ RNA-induced toxicity in a DM1 transgenic *Drosophila* model. The ligand has been further used as the foundation for the rational design of multitarget agents for DM1 that bind to CTG^exp^ DNA and inhibit the formation of the r(CUG)^exp^ transcript, bind to r(CUG)^exp^ and inhibit sequestration of MBNL1, and cleave r(CUG)^exp^ in an RNase-like manner ([@bib68]). This work stands as a particularly notable and relatively rare use of rational design of RNA-binding small molecules with validated activity in an animal model. In addition to this work, other groups have reported several other r(CUG)^exp^-binding compounds. For example, the Disney group reported a substituted naphthyridine (**6**, [Figure 1](#fig1){ref-type="fig"}C) that was identified by high-throughput screening, and was shown to inhibit the r(CUG)^exp^-MBNL1 interaction with an IC~50~ of 2 ± 0.4 μM using a FRET-based assay ([@bib18], [@bib21]). The naphthyridine binds to r(CUG)~12~ with a K~D~ of 125 nM and interacts with the UU loops in r(CUG)^exp^ to displace MBNL1. In cell models, **6** improved DM1-associated pre-mRNA splicing defects with specificity for MBNL1-regulated splicing events and caused reductions in nuclear foci formation. Compound **6** has also been subsequently identified by the Disney laboratory to be an inhibitor of miR-544 (see below) ([@bib44]). The Disney laboratory also reported benzimidazoles (**7**, [Figure 1](#fig1){ref-type="fig"}C) identified by screening of an RNA-focused small-molecule library, and oligomeric Hoechst dye-like compounds that bind r(CUG)^exp^ in cells and had promising effects on DM1-associated defects in cell models ([@bib20], [@bib78], [@bib83]).

Another design-based approach for the recognition of specific RNA structures comes from the Chenoweth group, which has recently reported several papers describing the use of triptycene-based molecular scaffolds to recognize RNA junctions. Three-way junctions are ubiquitous throughout the transcriptome, although few small molecules that recognize them are known. The Chenoweth group initially reported a simple triptycene functionalized with cationic groups that bound to both DNA and RNA three-way junctions, and demonstrated that these compounds exhibit cell permeability as well as cytotoxicity ([@bib2], [@bib3]). Further work showed that diverse triptycene molecules can be synthesized in a modular and efficient fashion, including solid-phase methods that are likely to have use in the preparation of libraries of triptycenes going forward, with the potential for specific junction recognition ([@bib5], [@bib101]). Finally, a recent report demonstrated that functionalized triptycenes such as **8** ([Figure 1](#fig1){ref-type="fig"}D) can also be used to modulate the *Escherichia coli* rpoH RNA temperature sensor, indicating utility in recognizing RNA structures in bacteria as well ([@bib4]). To date, most of the work in this area has focused on molecular recognition and the development of synthetic methods to access new triptycene scaffolds; however, it is clear that this approach has potential for broad applications in RNA recognition and targeting in future efforts.

In another structure-based approach, [@bib75] performed an in silico screen to discover compounds that target the frameshifting signal pseudoknot in the severe acute respiratory syndrome coronavirus (SARS-CoV). SARS-CoV utilizes an essential programmed −1 ribosomal frameshift (−1 RF) to synthesize key replication components. The stability and structure of the RNA pseudoknot present in the −1 RF site is essential for efficient frameshifting and viral replication, indicating that it may be a valuable target for small molecules. The authors used a 3D structural model of the SARS pseudoknot to perform a virtual ligand screen. Docking of approximately 80,000 compounds from the commercially available chemical database LeadQuest produced a set of high-ranking compounds. Hit validation was performed using a pseudoknot-driven dual luciferase reporter assay in both biochemical and cell-based assays, and a novel ligand that inhibits the −1 RF of SARS-CoV was identified that dramatically decreased the −1 RF in vitro and inhibited −1 RF efficiency in HEK293 cells with an IC~50~ of approximately 0.45 μM (**9**, [Figure 1](#fig1){ref-type="fig"}E). Selectivity was evaluated using similar reporter assays on the pseudoknot from the pea enation mosaic virus, where the compound had no activity. In a later report by Woodside, binding studies by surface plasmon resonance revealed an apparent K~D~ of 210 ± 20 μM ([@bib81]). It remains unclear how a compound with this K~D~ could have such potent cellular effects. Finally, analysis using optical tweezers revealed that ligand binding appears to influence the ensemble of conformations populated by the RNA, rather than influencing its mechanical stability. Based on these studies, the authors propose a mechanism whereby the ligand reduces −1 RF efficiency by decreasing the conformational plasticity of the SARS pseudoknot ([@bib81]).

In addition to designing ligands de novo on the basis of RNA structure, a related strategy is to redesign cognate ligands for a particular RNA. This is primarily applicable to riboswitches, naturally occurring aptamers that regulate gene expression by changing conformation in the presence of a metabolite or small-molecule ligand. Over the last decade, several groups have used structure-guided rational design to identify and optimize small molecules that bind to selected riboswitch aptamers based on the structures of their cognate ligands, including small molecules targeting cyclic diguanylate monophosphate ([@bib36]), glmS ([@bib7], [@bib61]), purine ([@bib41]), and lysine ([@bib8]) riboswitches. In some cases, synthetic or natural analogs of cognate ligands have also demonstrated potent antibacterial activity, suggesting the potential for developing riboswitch-targeting antibiotics ([@bib8], [@bib53], [@bib57], [@bib63], [@bib72]). Recently, an analog of riboflavin, 5FDQD, was designed via medicinal chemistry optimization to bind to riboswitches that recognize the natural coenzyme flavin mononucleotide (FMN) and regulate the homeostasis of FMN and riboflavin, as reported by the Breaker laboratory in collaboration with several industrial groups ([@bib9]). In vitro, 5FDQD binds to and triggers function of an FMN riboswitch, shows antibacterial activity against *Clostridium difficile*, and prevents antibiotic-induced *C. difficile* infection (CDI) in mice nearly as effectively as fidaxomicin, a current CDI treatment. It is clear that in many cases where substantial information about the structure and dynamics of a given RNA is available, this information may be leveraged in the design of small-molecule binders with good affinity and biological activity.

Informatics-Based Approaches {#sec1.3}
----------------------------

Another powerful tool that has successfully been used to design small molecules that bind to RNA targets is the informatics-driven, rational design approach termed Inforna, developed by the Disney laboratory. Inforna utilizes a database of experimentally determined RNA-motif-small-molecule interactions identified through a selection-based strategy called two-dimensional combinatorial screening (2DCS) and structure-activity relationships through sequencing (StARTS) ([@bib31]). In brief, a small-molecule library is conjugated to an agarose microarray surface, which is then probed for binding to a library of small RNA motifs, including hairpins, loops, or bulges, that are likely to be found as components of larger cellular RNAs. Quantification of specific bound RNAs is accomplished by excision of each individual spot of the array and sequencing of the corresponding bound oligonucleotides. Next, StARTS is used to score each RNA-motif-small-molecule interaction ([@bib94]). Inforna can be used to identify lead compounds for an RNA of interest by comparing the structural motifs present in a target RNA with the motifs in the database of annotated RNA-motif-small-molecule interactions derived from 2DCS. For a given RNA of interest, the Inforna software provides the targetable structural motifs for the input RNA, the corresponding lead small-molecule hits, and the fitness of the predicted RNA-small-molecule interactions as determined by StARTS analysis ([@bib95]). A powerful demonstration of the abilities of Inforna is the discovery of a compound that binds to the miRNA miR-96 and inhibits miR-96 biogenesis with selectivity similar to that of an miR-96 antagomir ([@bib95]). The discovered small molecule inhibits Drosha processing of pri-miR-96, leading to the upregulation of its target FOXO1 and the induction of apoptosis in MCF7 breast cancer cells.

Recently, the Disney laboratory has successfully employed Inforna to identify small-molecule ligands for several other disease-associated RNA structures. One prominent example is the repeat expansion r(GGGGCC)^exp^, the most common genetic cause of frontotemporal dementia and ALS (c9FTD/ALS) ([@bib91]). This repeat expansion RNA forms nuclear foci that sequester various RNA-binding proteins, causing toxicity and undergoing repeat-associated non-ATG (RAN) translation to produce c9RAN proteins that form neuronal inclusions throughout the CNS. Based on the determined mixed hairpin/G-quadruplex structure of r(GGGGCC)^exp^, lead small molecules that bind to the RNA were identified using Inforna ([Figure 2](#fig2){ref-type="fig"} ). The hit compounds were experimentally screened using a biochemical TO-PRO-1 displacement assay, and three lead compounds were identified and validated. Kinetic binding studies with r(GGGGCC)~8~ revealed K~D~s of 16, 10, and 9.7 μM for compounds **10**, **11**, and **12**, respectively ([Figure 2](#fig2){ref-type="fig"}). The compounds showed similar binding affinities to r(CGG)~12~ and r(GGCC)~4~, both of which possess 1 × 1 GG internal loops structurally similar to that of r(GGGGCC)~8~; however, the compounds had significantly decreased binding affinities for a hairpin with a fully paired stem, demonstrating modest selectivity for 1 × 1 GG internal loops. Furthermore, the compounds successfully engaged r(GGGGCC)~66~ RNA in COS7 cells as demonstrated by competitive Chem-CLIP, validating binding in cellulo. In HEK293 cells, expression of r(GGGGCC)~66~ resulted in the synthesis of poly(GP) and poly(GA) proteins through RAN translation, and treatment with two of the lead compounds (**11** and **12**) significantly decreased both poly(GP) and poly(GA) protein levels, demonstrating the ability of the small molecules to inhibit RAN translation. These compounds were also capable of inhibiting nuclear foci formation as determined by RNA fluorescence in situ hybridization. In addition, compound **12** inhibited RAN translation and foci formation in iNeurons with the r(GGGGCC) expansion, suggesting the potential of a small-molecule inhibitor of r(GGGGCC)^exp^ as a lead structure for therapeutic development for treatment of c9FTD/ALS.Figure 2Application of Inforna to the Identification of Small Molecules that Bind to Disease-Associated RNAsA database of RNA motif-small molecule interactions was used to predict compounds that bind to the 1 × 1 nucleotide GG internal loops present in the c9FTD/ALS-associated r(GGGGCC)^exp^ (top, blue), or to the 1 × 1 nucleotide UU internal loops present in the Dicer and Drosha processing sites of the cancer associated miR-544 hairpin precursor (bottom, red). Structures of validated lead compounds that bind to r(GGGGCC)~8~ and the miR-544 hairpin precursor are shown in blue and red, respectively ([@bib44], [@bib95]).

Similarly, the Disney and Finney laboratories used Inforna to identify small molecules that bind to the miRNA miR-544, which silences mammalian target of rapamycin (mTOR), as a means to interrogate the role of miR-544 in tumor cell growth under hypoxic conditions ([@bib44]). The precursor hairpin structure of miR-544 was parsed into its composite motifs (the 1 × 1 nucleotide UU internal loops present in the Dicer and Drosha processing sites), which were then screened in Inforna ([Figure 2](#fig2){ref-type="fig"}). Identified compounds were screened and tested for their ability to modulate miR-544 biogenesis, and five potential lead compounds were identified. The most potent compound (**6**, [Figure 2](#fig2){ref-type="fig"}) successfully disrupted miR-544-mediated inhibition of its validated target BMI1 as demonstrated by a fluorescence-based reporter assay in cellulo, and caused accumulation of pre-miR-544 and a decrease in mature miR-544 levels by qRT-PCR. The compound selectively bound RNAs containing the 1 × 1 nucleotide UU internal loop of the Dicer and Drosha sites over control RNAs containing a UA pair with binding constants in the midnanomolar range, and showed no binding to a DNA control by gel-shift assay. Impressively, microarray analysis of cells treated with **6** revealed changes in mRNA and miRNA expression similar to that of cells transfected with the miR-544 antagomir, indicating that the compound is as selective as an oligonucleotide-based antisense inhibitor. However, the Disney laboratory also reported that **6** binds to r(CUG)^exp^ RNA as well (see discussion above) ([@bib18], [@bib21]). In immunodeficient mice implanted with MDA-MB-231-GFP-luc cells, pretreatment with **6** as well as postimplantation intraperitoneal injection impeded tumor growth compared with untreated cells, and qRT-PCR analysis of developed tumors revealed decreased levels of miR-544, HIF-1α, and ATM and increased levels of pre-miR-544 and mTOR. Taken together, this work stands as a powerful example of the Inforna platform\'s ability to identify highly selective RNA-binding small molecules that modulate miRNA biogenesis in vivo. Combined with the r(GGGGCC)^exp^ and other examples, primarily focused on precursor miRNA inhibitors ([@bib44], [@bib62], [@bib95]), it is clear that Inforna has matured as a highly useful tool for the discovery of RNA-binding molecules.

Fragment-Based Approaches {#sec1.4}
-------------------------

Fragment-based drug discovery (FBDD) is a modern method for the development of highly potent inhibitors with desirable, drug-like properties. In brief, this method employs sensitive biophysical techniques to identify low molecular weight compounds with weak but specific interactions to the biomolecule of interest. Once identified, compounds may be elaborated via multiple strategies into potent, selective inhibitors. While this method has enjoyed much success in developing enzyme inhibitors, it has only recently begun to be used broadly in the arena of RNA-binding small molecules ([@bib24]).

For example, [@bib23] reported a fragment-based approach for identifying novel thiamine pyrophosphate (TPP) riboswitch ligands. TPP riboswitches are located in the 5′ UTR of various bacterial mRNAs and regulate the expression of the *thiMD* operon by changing conformation in the presence of TPP. In this study, a library of 1,300 structurally and chemically diverse fragments that were "rule of three" compliant (molecular weight ≤300 Da; c log p ≤ 3; no more than three hydrogen-bond donors and acceptors) and had ≥95% purity and ≥1 mM aqueous solubility was screened by equilibrium dialysis, whereby \[^3^H\]thiamine and fragments were placed in a separate chamber from the riboswitch and allowed to equilibrate. The concentration of the radiolabeled ligand was then measured to identify fragments that disrupt the thiamine-RNA interaction. From this screen, 20 hits were initially identified and further validated by NMR. Selectivity of the hits was also assessed using equilibrium dialysis against a structurally different lysine riboswitch present in *Bacillus subtilis lysC*. Several of the compounds (**13--16**, [Figure 3](#fig3){ref-type="fig"}A) were later investigated in the Weeks and Ferré-D'Amaré laboratories through in-depth biophysical studies to provide insight into the mechanism of binding of the fragments ([@bib96]). Here, cocrystal structures of the *E. coli thiM* TPP riboswitch with the fragments revealed that the fragment occupies the same binding site as the aminopyridine of TPP. However, binding of the fragments resulted in a rearrangement of an unoccupied site, G72 ([Figure 3](#fig3){ref-type="fig"}A). Additional studies via SAXS and SHAPE showed that complete folding is achieved when TPP is bound and only partial folding when fragment **16** is bound. Taken together, these results suggest that the small-molecule fragments are competitive with TPP itself, but may stabilize different folding pathways.Figure 3Fragment-Based Discovery of RNA-Binding Molecules(A) Chemical structures of four TPP riboswitch-binding fragments (left) and the cocrystal structure of TPP riboswitch bound to **16**, depicting a rearrangement of G72 (right) ([@bib23], [@bib96]).(B) ^19^F-NMR fragment-based screening strategy to identify chemically diverse compounds that bind to TERRA (left), in which ^19^F-NMR signals are perturbed or broadened by compounds binding. Chemical structures of four representative hits that bind to TERRA~2~ are shown on the right. Fluorines are indicated in red ([@bib38]).(C) Fragment-based screening hit (DPQ) and improved analog that bind to the influenza A promoter RNA. Also shown is a structure of the promoter RNA in complex with DPQ ([@bib11], [@bib58]).

The FBDD strategy has also been implemented to identify novel and chemically diverse fragments that bind to TERRA in the Campos-Olivas and González laboratories ([@bib38]). The r(UUAGGG)~n~ sequence folds into G-quadruplexes that are required for telomere heterochromatin formation in cancer cells, and is therefore an attractive anticancer target. A library of 355 fluorinated fragment compounds was screened against RNA containing 16 r(UUAGGG) repeats (TERRA~16~) using ^19^F-NMR spectroscopy ([Figure 3](#fig3){ref-type="fig"}B). Spectra of the fragments were collected in the presence and absence of TERRA~16~ and compared to identify perturbations in the peak intensity and width upon addition of the RNA target. Of the 20 molecules identified by the initial screening, seven were further validated (representative hits, **17**--**20**, are shown in [Figure 3](#fig3){ref-type="fig"}B). Six of these compounds were shown to interact with a shorter TERRA construct of two repeats (TERRA~2~) and four compounds demonstrated selectivity for TERRA over a duplex DNA and phenylalanine tRNA by ^1^H- and ^19^F-NMR, respectively. While all of the compounds interacted with the DNA analog of TERRA~2~, the compounds were shown to favor the parallel conformation, which is the predominant conformation in the RNA G-quadruplexes present in TERRA.

In the context of viral RNA, Göbel and coworkers reported a successful screen for fragments that inhibit the HIV Tat/TAR interaction using an FRET displacement assay ([@bib103]). They validated fragment binding to TAR RNA using ^1^H-NMR and ^1^H-^1^H nuclear Overhauser effect spectroscopy (NOESY) experiments and identified several hits with affinities ranging from 40 to 20,000 μM. While Tat/TAR is a well-studied target, new viral RNAs have also been evaluated by fragment-based approaches. A powerful example of this has been the study of genomic elements of the influenza A virus. The influenza A viral genome contains a promoter region, which is a highly conserved sequence located on both the 5′ and 3′ termini that folds into a partial duplex and binds to the RNA-dependent RNA polymerase (RdRp). This promoter region has been considered an attractive drug target, and previous studies have demonstrated that neomycin binds with a submicromolar affinity ([@bib54]). Subsequently, the Varani and Choi groups reported a fragment-based screen for small molecules that bind to the influenza A virus promoter ([@bib58]). A library of 4,279 fragments was evaluated by RNA-observed ^1^H-NMR. Through this screen, 6,7-dimethoxy-2-(1-piperazinyl)-4-quinazolinamine (DPQ, **21**) was identified and studied as an inhibitor ([Figure 3](#fig3){ref-type="fig"}C). DPQ has an affinity of 61 μM for the hairpin and an IC~50~ of 549 μM against influenza A. The binding mode of DPQ was investigated by NMR, and the structure revealed that the compound binds to the promoter in the major groove of its internal loop. Inhibition may occur due to a structural change that prevents the bending of the helix and the association of RdRp subunits. Subsequent work focused on SAR studies with DPQ to improve its cellular activity against influenza ([@bib11]). Since the piperazinyl secondary amine was not involved in any significant contacts ([Figure 3](#fig3){ref-type="fig"}C), 15 analogs with modifications to this group were prepared. Of these compounds, **22** displayed an improved antiviral IC~50~ of 44 μM while maintaining a K~D~ value comparable with that of DPQ. Although fragment-based approaches have yet to yield a selective, high-affinity RNA binder, going forward it is probable that these approaches will play a large role in assessing the druggability of newly discovered RNA structures. Thus, the value of fragment-based approaches may be not only in developing leads for specific RNA structures, but also in helping to decide which RNA structures are druggable at all.

Small-Molecule Microarray Screening {#sec1.5}
-----------------------------------

The small-molecule microarray (SMM) approach was originally developed by Schreiber for the discovery of ligands for "undruggable" proteins such as transcription factors and has been widely applied in that field ([@bib12], [@bib13], [@bib47], [@bib50], [@bib52], [@bib55]). In this technique, small molecules are spatially arrayed with a robotic microarrayer and covalently linked to a glass surface. Next, the array is incubated with a fluorescently labeled biomolecule. Arrays are imaged using a fluorescence scanner, and fluorescence intensity is quantified for each spot on the array. A statistical analysis reveals spots with large increases in fluorescence upon incubation, corresponding with discrete molecular interactions between the oligonucleotide and associated small molecule.

Our laboratory has advanced the use of SMMs as a platform for the identification of small molecules that bind to structured nucleic acids, building on the original work that employed aminoglycosides ([Figure 4](#fig4){ref-type="fig"}A) ([@bib15], [@bib30]). First, we assembled a library of 20,000 drug-like compounds, each of which contains an amine or alcohol group to covalently react with the array surface. This library can be screened in less than a day with little optimization. In one example, we were able to identify a small molecule that binds to the HIV TAR hairpin ([@bib92]). A fluorescently labeled TAR hairpin was screened against our library on the SMM platform, and three compounds were identified that bound to TAR but not other oligonucleotides, including an miR-21 hairpin and three distinct DNA sequences. A derivative of one of these compounds (**23**) bound reversibly to the TAR hairpin with a K~D~ of 2 μM ([Figure 4](#fig4){ref-type="fig"}B). SHAPE profiling was used to probe compound binding in the context of the entire HIV 5′ UTR, and ligand binding could be mapped specifically to the TAR hairpin and not other structural elements ([Figure 4](#fig4){ref-type="fig"}B). Thus, microarrays are useful to identify potent, noncationic compounds that bind selectively to RNA structures even as simple as hairpins in the context of complex structures such as UTRs. In a more recent study, we used the SMM platform to identify molecules that selectively bind to the DNA G-quadruplex responsible for controlling the expression of MYC, an oncogene that is dysregulated in many cancers ([@bib35]). Given the prevalence of quadruplexes in the promoter regions of oncogenes ([@bib71]) and in mRNA, it is highly likely that SMMs will be a useful technology for identifying selective inhibitors of RNA quadruplexes as well.Figure 4Use of Small-Molecule Microarrays to Identify RNA-Binding Molecules(A) Small-molecule microarray screening approach.(B) Structure of a molecule discovered by SMM screening to bind specifically to the HIV TAR hairpin, but not other structural elements of the HIV 5′ UTR ([@bib92]).

Dynamic Combinatorial Screening {#sec1.6}
-------------------------------

Dynamic combinatorial chemistry (DCC) is a powerful method of evolution-driven small-molecule discovery. Using DCC, small-molecule fragments can undergo recombination in the presence of a target of interest, producing substantial chemical diversity, thereby allowing selection and amplification of the highest-affinity binders through an equilibrium shift. A resin-bound DCC (RBDCC) approach was used by the Miller laboratory to screen a library of 11,325 compounds for small molecules that bind to r(CUG)^exp^ involved in DM1 ([@bib39]). The library was created from 150 resin-bound, cysteine-containing peptides and an identical set of solution-phase peptides, where formation of a disulfide bond between the resin-bound and solution-phase cysteines provides the combinatorial library ([Figure 5](#fig5){ref-type="fig"}A). The library was screened with a fluorescently labeled r(CUG)~10~, and four compounds were identified with low micromolar binding affinities for r(CUG)~10~. These compounds inhibited the (CUG)~109~-MBNL1 binding interaction with K~i~s ranging from 2.8 to 3.8 μM in an enzyme fragment complementation assay. Second-generation binders (**24** and **25**, [Figure 5](#fig5){ref-type="fig"}B) showed enhanced selectivity by surface plasmon resonance with **25** demonstrating a significant preference for (CUG)~10~ over (CCUG)~10~ RNA, a 38-fold preference versus (CAG)~10~, no measurable binding to a duplex CUG-CAG sequence, and an 89-fold reduction in binding to HIV-1 FSS RNA. These improved compounds blocked DM1-associated translational defects in cell-culture models, and, importantly, two compounds (**24** and **25**) successfully improved alternative pre-mRNA splicing defects in a DM1 mouse model, suggesting the therapeutic application of a small molecule that targets r(CUG)^exp^ ([@bib69]).Figure 5Dynamic Combinatorial Approaches to Identify RNA-Binding MoleculesGeneric depiction of a dynamic combinatorial chemistry approach (A). Targets for dynamic combinatorial chemistry include both (B) DM1-associated (CUG) repeat RNA and (C) the HIV-1 frameshift-inducing RNA stem loop ([@bib39], [@bib49], [@bib70]). RBDCL, resin-bound dynamic combinatorial library.

RBDCC was further applied by the Miller laboratory to the discovery of compounds that bind to an RNA target that regulates frameshifting in HIV, the precise control of which is crucial for viral proliferation ([@bib65]). The production of the essential Gag-Pol polyprotein in HIV requires a −1 nucleotide ribosomal frameshift that is in part directed by a highly conserved downstream RNA stem loop. RBDCC with a library of 11,325 members was used to identify a set of disulfide-containing peptides that bind to the HIV-1 FSS RNA ([Figure 5](#fig5){ref-type="fig"}C). The lead compound (**26**) had an affinity of 4.1 ± 2.4 μM for HIV-1 FSS as determined by surface plasmon resonance and a solution-phase K~D~ of 0.35 ± 1.1 μM by fluorescence titration ([@bib65]). Furthermore, the presence of either excess competitor yeast tRNA or total yeast RNA had no effect on the binding affinity, indicating good selectivity ([@bib74]). No saturable binding was observed to a DNA homolog of the HIV-1 FSS or to unrelated RNA hairpins, and single or multiple mutations in the loop region of the HIV-1 FSS caused 2- and 4-fold reductions in the binding, respectively. Optimization of **26** produced an olefin bioisostere that had enhanced biostability and comparable affinity ([@bib74]). Additional SAR efforts produced high-affinity binders (**27** and **28**) that altered frameshifting in HEK293FT cells and strongly inhibited viral infectivity in a pseudotyped HIV assay ([@bib70]). A series of *N*-methyl derivatives also bind the HIV-1 FSS RNA with low nanomolar affinity and high selectivity. These compounds readily penetrated cell membranes and inhibited infectivity in a pseudotyped HIV assay, which correlated with compound-induced changes in the expression of the Gag-Pol polyprotein ([@bib49]). These two targets demonstrate that RBDCC is a powerful approach to identifying potent, selective, biologically active RNA-binding small molecules by leveraging the power of selection approaches.

Phenotypic Assays {#sec1.7}
-----------------

In addition to the biochemical and biophysical approaches discussed above, phenotypic assays have also shown great promise for the discovery of biologically active, RNA-binding small molecules. These approaches use a phenotypic readout, such as a reporter gene assay, to report on the activity of a particular RNA or RNA-associated pathway in intact cells. For example, the Deiters laboratory has demonstrated the use of reporter gene assays to identify compounds that act against specific miRNAs, including miR-21 ([@bib43], [@bib66]) and miR-122 ([@bib102]). However, it is not clear whether these compounds bind directly to the miRNA itself or to another intracellular target. Another prominent example of phenotypic screening comes from the study of spinal muscular atrophy (SMA), a life-threatening motor neuron disease that is caused by the deficiency of the survival of motor neuron (SMN) protein ([@bib73]). In SMA cells, the lack of fully functional SMN protein is a consequence of homozygous deletion of the *SMN1* gene. Both the *SMN1* and *SMN2* genes can produce the SMN protein. Although the *SMN2* gene is able to partially compensate for low levels of the SMN protein, a single-nucleotide transition in *SMN2* results in the exclusion of exon 7 and ultimately in a further decrease in full-length (FL) SMN mRNA and protein production. Researchers at the Novartis Institutes for Biomedical Research utilized a phenotypic assay to screen for small molecules with the ability to reduce exclusion of exon 7 and increase FL-SMN protein levels. Two *SMN2* reporter genes, FL and Δ7, were designed within the NSC34 motor neuron cell line to indicate either exon 7 inclusion or exclusion, respectively ([Figure 6](#fig6){ref-type="fig"}A). Compounds from the Novartis compound library (∼1.4 × 10^6^ compounds) were screened against the two reporter genes, and those that gave complementary results reporting a simultaneous increase in FL-SMN and a decrease in Δ7 were reported as hits, leading to the identification of NVS-SM2 (**29**, [Figure 6](#fig6){ref-type="fig"}A). Gene-expression analysis by RNA sequencing (RNA-seq) revealed that the compound regulates a discrete set of splicing variants, indicating fairly selective splicing modulation. Furthermore, **29** demonstrated promising in vivo activity, while NVS-SM3 (**30**), the structure of which closely resembles that of NVS-SM2, was inactive ([Figure 6](#fig6){ref-type="fig"}A). Total correlation spectroscopy NMR and surface plasmon resonance confirmed that **30** binds directly to the U1 small nuclear ribonucleoprotein (snRNP) 5′ splice site (ss), while computational modeling was used to suggest a binding mode of the compound to the U1 snRNP-SMN pre-mRNA ([Figure 6](#fig6){ref-type="fig"}A). Taken together, these results suggest a model in which NVS-SM2 functions by binding near the nGA site, stabilizing the U1 snRNP-SMN exon 7 5′ ss complex, and therefore enabling exon 7 inclusion. It is also of note that this work is not the first example of SMN2 splicing inhibitors. In an earlier example, a team from PTC Therapeutics and Hoffmann-La Roche discovered a series of compounds that display excellent in vivo activity in modulating the splicing of SMN2 and potential for the treatment of SMA ([@bib67]). These molecules display remarkably high specificity as measured by RNA-seq and oral bioavailability in a mouse model for SMA. It is speculated that these molecules interact with specific RNA structures or RNA-protein complexes within the SMN2 pre-mRNA, although the specific binding targets of these molecules have yet to be identified.Figure 6Use of Phenotypic Assays to Identify RNA-Binding Molecules(A) Schematic of a reporter gene assay that utilizes luciferase expression to measure exon 7 exclusion/inclusion in SM2 splicing. Chemical structures of NVS-SM2 and its inactive analog NVS-SM3. Putative binding site of NVS-SM2 within the crystal structure of the U1 snRNP-SMN pre-mRNA with rainbow coloring indicating 5′ (blue) to 3′ (red) (bottom) ([@bib73]).(B) Depiction of a whole-cell phenotypic screening assay (top left) to identify inhibitors of riboflavin biosynthesis (right). In the absence of riboflavin, ribocil produces a clear zone as a result of growth inhibition. Cocrystal structure of the FMN riboswitch bound to ribocil B (bottom left) ([@bib51]).

In another example, researchers at the Merck Research Laboratories used a phenotypic assay to discover a riboswitch-binding small molecule ([@bib51]). The concept of targeting riboswitches has been a long-standing goal since their initial discovery in 2002 ([@bib6], [@bib98]), and most approaches have focused on redesigning cognate ligands to develop improved inhibitors, as described above. In this work, a small molecule deemed ribocil was reported as an inhibitor of the FMN riboswitch, a structured, metabolite-responsive element in the promoter region of the *ribB* gene. Due to its role in riboflavin biosynthesis, the FMN riboswitch is essential for bacterial growth, and is therefore an attractive target for antibacterial activity, as previously demonstrated ([@bib9]). Deletion strains missing two genes that play a role in earlier steps of riboflavin biosynthesis, *ribA* and *ribB*, were shown to have a significant reduction in bacterial burden compared with the wild-type control. An internal library of ∼57,000 small molecules was screened in a phenotypic assay to identify lead compounds that exhibit such antibacterial effects and produce a clear zone of growth inhibition ([Figure 6](#fig6){ref-type="fig"}B). One hit compound, racemic ribocil, caused not only a reduction in bacterial burden but also a reduction in the levels of FAD and FMN, effects that had also been observed in deletion strains. Further investigation showed only one of the enantiomers of ribocil, ribocil B (**31**) was active, whereas ribocil A (**32**) was inactive. The specific target interactions were determined by identifying 19 ribocil-resistant mutants, all of which contained mutations in the FMN riboswitch within the *ribB* gene, pointing to this structured RNA as the small-molecule target. Furthermore, ribocil displayed selective microbiological activity against *E. coli* MB5746 possessing either the native FMN riboswitch or orthologous FMN aptamers (which was suppressed by the addition of exogenous riboflavin), and was inactive against yeast and human cells that lack the cognate target. The *Fusobacterium nucleatum* FMN aptamer was cocrystallized with ribocil to identify the key interactions between the riboswitch and the ligand ([Figure 6](#fig6){ref-type="fig"}B). Remarkably, ribocil appears to make many of the same interactions with the riboswitch as the cognate ligand, and despite having no apparent structural similarity to FMN itself, it has a K~D~ of 16 nM. The discovery of ribocil is a robust demonstration that phenotypic screens are an excellent way to identify drug-like chemical structures that bind to RNA.

Conclusion {#sec1.8}
----------

In summary, the increased understanding of RNA structure and function is likely to lead to a broad variety of potential therapeutic targets for small molecules. The continued development of technologies for druggability assessment and inhibitor discovery against new RNA targets will be invaluable. For example, targeting a riboswitch, which has evolved to bind to a small-molecule metabolite, is likely be a challenge very different from targeting an lncRNA that functions by sequestering proteins through protein-RNA interactions. In fact it is probable that like proteins, different RNAs will be of variable difficulty as targets for small-molecule ligands, regardless of their biological or pharmacological significance. While early results suggest that it is possible to design or identify small molecules that modulate the function of at least some RNAs, many challenges remain, and the question of which RNAs are druggable is far from settled. Here the application of fragment-based approaches may be useful, as the hit rates of fragment-based screens have been used to assess the druggability of protein targets ([@bib104]). Another challenge will be overcoming the problem of specificity and selectivity, which remains a major barrier for RNA-binding molecules. For example, there is currently no general method to probe transcriptome-wide binding of a small molecule, and such an advance would be transformative. However, the implementation of structure-based and high-throughput screening methods described here have proved lucrative at identifying new biologically active small-molecule scaffolds that bind RNA with both high affinity and some specificity. Many of these recently developed small molecules are structurally distinct from historic RNA-binding scaffolds, display good physicochemical properties, and have proved active in cell-based and animal models of disease, supporting the role of RNAs as a therapeutic target. The continued success of these technologies will provide new openings and opportunities for the development of innovative therapeutics that target RNA in the upcoming years.
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